LENSAR’s (LNSR) Hold Rating Reiterated at Lake Street Capital

LENSAR (NASDAQ:LNSR)‘s stock had its “hold” rating reiterated by research analysts at Lake Street Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $15.00 price target on the stock, down from their prior price target of $16.00. Lake Street Capital’s price objective would indicate a potential upside of 5.49% from the company’s current price.

LENSAR Trading Down 4.0 %

LNSR stock traded down $0.60 during trading on Monday, hitting $14.22. The company had a trading volume of 618,733 shares, compared to its average volume of 54,567. The stock has a market cap of $167.64 million, a PE ratio of -9.74 and a beta of 0.62. The business has a 50-day moving average of $11.44 and a 200-day moving average of $8.19. LENSAR has a one year low of $2.67 and a one year high of $17.31.

LENSAR (NASDAQ:LNSR) last announced its earnings results on Thursday, February 27th. The company reported ($1.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.40). The firm had revenue of $16.73 million for the quarter, compared to the consensus estimate of $14.95 million. LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%.

Hedge Funds Weigh In On LENSAR

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in LENSAR by 3.5% in the third quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock valued at $460,000 after acquiring an additional 3,423 shares during the period. Atria Investments Inc increased its stake in LENSAR by 28.2% during the 4th quarter. Atria Investments Inc now owns 26,055 shares of the company’s stock valued at $233,000 after purchasing an additional 5,729 shares in the last quarter. Essex Investment Management Co. LLC raised its holdings in LENSAR by 18.3% during the fourth quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company’s stock worth $357,000 after buying an additional 6,184 shares during the last quarter. Evernest Financial Advisors LLC acquired a new position in LENSAR during the fourth quarter worth $174,000. Finally, Bailard Inc. bought a new position in shares of LENSAR in the fourth quarter valued at $181,000. Institutional investors own 40.15% of the company’s stock.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.